<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336770">
  <stage>Registered</stage>
  <submitdate>19/04/2011</submitdate>
  <approvaldate>10/05/2011</approvaldate>
  <actrnumber>ACTRN12611000490976</actrnumber>
  <trial_identification>
    <studytitle>Obsessive Compulsive Spectrum Disorders and Quality of Life in patients with Idiopathic Parkinson's Disease</studytitle>
    <scientifictitle>Obsessive Compulsive Spectrum Disorders and Quality of Life in patients with Idiopathic Parkinson's Disease</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Parkinson's Disease</healthcondition>
    <healthcondition>Obsessive Compulsive Spectrum Disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Parkinson's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with diagnosed with Idiopathic Parkinson's Disease

Patients will undergo a Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MOCA), Quality of Life (QoL) using the Parkinsons disease Questionnaire (PDQ-39), and Questionnaire for Impulsive-Compulsive Disorders in Parkinsons disease (QUIP-Anytime During Parkinsons disease-Full).  A neurologist will assess the patients Parkinsons disease and staging using the Unified Parkinsons disease Rating Scale (UPDRS), as well as co morbidities and medication use. A psychiatrist will interview the patient for Obsessive-Compulsive Disorder Related/Spectrum Disorders (Obsessive-Compulsive-Spectrum Disorders) using the Expanded Structured Clinical Interview for DSM-IVTR.

Patients will be recruited over a 26 month period</interventions>
    <comparator>no treatment</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The quality of life of Parkinson's patients assessed by The Parkinson's Disease Questionnaire (PDQ-39).</outcome>
      <timepoint>During Visit</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>% of Parkinson's patients diagnosed with Obsessive Compulsive Spectrum  Disorders (OCSD).

Patients will be diagnosed by psychiatrist using the Mini International Neuropsychiatric Interview (MINI).</outcome>
      <timepoint>During Visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patient's diagnosed with Idiopathic Parkinson's Disease</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients diagnosed with schizophrenia or bipolar disorders</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2747</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Martin Krause</primarysponsorname>
    <primarysponsoraddress>Nepean Hospital
Level 5 South Block
PO Box 63
PENRITH NSW 2751</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Parkinson's New South Wales Inc</fundingname>
      <fundingaddress>PO Box 71
NORTH RYDE BC NSW 1670</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Nepean Medical Research Foundation</fundingname>
      <fundingaddress>PO Box 82
EMU PLAINS  NSW  2750</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Victor Fung</othercollaboratorname>
      <othercollaboratoraddress>Westmead Hospital
PO BOX 533
WENTWORTHVILLE NSW 2145</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Parkinsons disease primarily affects the way a person is able to move or walk and causes muscle stiffness and tremor, which can be very disabling. However, these patients also suffer from non-motor symptoms. These non-motor symptoms include depression, cognitive impairment, and sleep disturbances. As the disease progresses these non-motor symptoms have been shown to have a greater impact on the patients quality of life (QoL).

Obsessive Compulsive Spectrum Disorders (OCSD) are a group of psychiatric disorders  that have been demonstrated in patient with Parkinsons disease. 

We hypothesized that OCSD have an impact on the QoL of patients with idiopathic disease. We aim evaluate the prevalence OCSD in patients with idiopathic Parkinsons disease and its impact on the patients QoL.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney West Area Health Service Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Office, Court Building
PO BOX 63
PENRITH NSW2751</ethicaddress>
      <ethicapprovaldate>11/06/2008</ethicapprovaldate>
      <hrec>08/026/08/NEPEAN/41</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Martin Krause</name>
      <address>Nepean Hospital
Level 5, South Block
PO BOX 63
PENRITH NSW 2751</address>
      <phone>+61 2 4734 4278</phone>
      <fax>+61 2 4734 1817</fax>
      <email>martin.krause@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Martin Krause</name>
      <address>Nepean Hospital
Level 5, South Block
PO BOX 63
PENRITH NSW 2751</address>
      <phone>+61 2 4734 4278</phone>
      <fax>+61 2 4734 1817</fax>
      <email>martin.krause@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Martin Krause</name>
      <address>Nepean Hopsital
Level 5, South Block
PO BOX 63
PENRITH NSW 2751</address>
      <phone>+61 2 4734 4278</phone>
      <fax>+61 2 4734 1817</fax>
      <email>martin.krause@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>